{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.75","upperLimit":"0.87","value":"0.82"},{"groupId":"OG001","lowerLimit":"0.75","upperLimit":"0.88","value":"0.83"},{"groupId":"OG002","lowerLimit":"0.60","upperLimit":"0.89","value":"0.79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"126"},{"groupId":"OG002","value":"35"}],"units":"Participants"}],"description":"A description, survival to relapse, of patterns of relapse after Doxorubicin, Bleomycin, Vincristine, Etoposide - Prednisone, Cyclophosphamide (ABVE-PC) and risk-adapted radiotherapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"All Patients","id":"OG000","title":"Group 1"},{"description":"risk-adapted radiation therapy","id":"OG001","title":"Group 6"},{"description":"no risk-adapted radiation therapy","id":"OG002","title":"Group 7"}],"paramType":"NUMBER","populationDescription":"161 patients began consolidation therapy: 126 patients received risk-adapted radiotherapy after consolidation therapy ABVE-PC and 35 did not.","reportingStatus":"POSTED","timeFrame":"3 years from enrollment","title":"Relapse-free Survival","type":"SECONDARY","unitOfMeasure":"Probability of survival"}